(Q35209410)

7 August 2017

1 reference

title

Mode of action of fibrates (English)

1 reference

7 August 2017

1

A. L. Catapano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1294939

10 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1294939

10 September 2022

publication date

1 December 1992

1 reference

full work available at URL

7 August 2017

https://api.elsevier.com/content/article/PII:104366189290232Z?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

https://api.elsevier.com/content/article/PII:104366189290232Z?httpAccept=text/plain

28 November 2023

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

28 November 2023

published in

Pharmacological Research

1 reference

7 August 2017

26

1 reference

7 August 2017

331-340

1 reference

7 August 2017

4

1 reference

Effects of fibrates on serum lipids and atherosclerosis

7 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia Effect of 2,2-dimethyl, 5(2,5-xylyloxy) valeric acid therapy

28 November 2023

2

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of eicosapentaenoic and docosahexaenoic acids on apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells

28 November 2023

3

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Suppression by diets rich in fish oil of very low density lipoprotein production in man.

28 November 2023

4

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia

28 November 2023

5

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

On the mechanism of action of atromid-S on triglyceride transport in man

28 November 2023

7

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Comparison of assay methods for selective measurement of plasma lipase. The effect of clofibrate on hepatic and lipoprotein lipase in normals and patients with hypertriglyceridemia

28 November 2023

11

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia

28 November 2023

12

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate

28 November 2023

13

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Increase of the lipoprotein-lipase activity in human skeletal muscle during clof ibrate administration

28 November 2023

14

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

28 November 2023

15

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Increase in Lipoprotein Lipase during Clofibrate Treatment of Hypertriglyceridemia in Patients on Hemodialysis

28 November 2023

16

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemias

28 November 2023

17

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial

28 November 2023

19

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia

28 November 2023

20

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

28 November 2023

21

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver

28 November 2023

23

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effect of bezafibrate on plasma lipid in a strain of genetically hypercholesterolemic RICO rats

28 November 2023

26

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of fibric acid derivatives on biliary lipid composition

28 November 2023

31

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man

28 November 2023

34

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects

28 November 2023

35

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Influence of etofibrate on low density lipoprotein metabolism

28 November 2023

36

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of clofibrate on sterol metabolism in the rat.

28 November 2023

38

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy

28 November 2023

39

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia

28 November 2023

40

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Current approaches to drug therapy for the hypercholesterolemic patient

28 November 2023

42

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B

28 November 2023

45

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Change in composition of high density lipoprotein during gemfibrozil therapy

28 November 2023

46

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Mechanism of action of gemfibrozil on lipoprotein metabolism

28 November 2023

47

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction

28 November 2023

48

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters

28 November 2023

50

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations

28 November 2023

51

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Regression of computer estimated femoral atherosclerosis after pronounced serum lipid lowering in patients with asymptomatic hyperlipidaemia

28 November 2023

52

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia

28 November 2023

53

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients

28 November 2023

54

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice

28 November 2023

56

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

High density lipoprotein alterations induced by bezafibrate in healthy male volunteers

28 November 2023

57

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Atherogenesis: a postprandial phenomenon

28 November 2023

59

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Role of triglyceride-rich lipoproteins in progression of atherosclerosis

28 November 2023

60

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase

28 November 2023

61

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Postprandial lipemia, fenofibrate and coronary artery disease

28 November 2023

62

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil

28 November 2023

63

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

The mysteries of lipoprotein(a)

28 November 2023

66

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Haemostatic function and cardiovascular death: early results of a prospective study

28 November 2023

69

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

Effect of clofibrate on blood viscosity in intermittent claudication.

28 November 2023

70

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia

28 November 2023

71

1 reference

https://api.crossref.org/works/10.1016/1043-6618(92)90232-Z

28 November 2023

Identifiers

1 reference

7 August 2017

1 reference